> Trialight public data. Index of pages: https://trialight.com/llms.txt > Web page: https://trialight.com/data/trial/c-forward-efficacy-and-safety-of-bem-rzr-vs-sof-vel-in-05ca8258-c0ba-4ce4-a169-221ec9d64e20 > Record changed: 2026-11-04 # C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV NCT07037277 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Phase Phase 3 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Recruitment status Active, not recruiting Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Participants 880 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Lead sponsor Atea Pharmaceuticals, Inc. Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Start date 2025-06-02 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) Number of sites 107 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Title and summary **Summary** The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV. Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Short title** C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Official title** An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Status and phase **Control arm** Active comparator Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Registry reports results** No Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Listing at source** Listed Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Recruitment status** Active, not recruiting Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Phase** Phase 3 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Study type** Interventional Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Dates **Completion date** 2027-03-01 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **First posted** 2025-06-25 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Registry last updated** 2026-06-29 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Primary completion date** 2026-12-01 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Start date** 2025-06-02 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Size and sites **Participants** 880 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Participant count basis** Estimated Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Planned participants** 880 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Protocol amendments** 0 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Number of sites** 107 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Sponsor and oversight **Data monitoring committee** Yes Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Registry sponsor category** Industry Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Lead sponsor** Atea Pharmaceuticals, Inc. Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Source registry** ClinicalTrials.gov Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Identifiers **Registry ID** NCT07037277 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **ClinicalTrials.gov ID** NCT07037277 Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) **Registry record** Open registry record Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Study design **Allocation** Randomised **Model** Parallel groups **Purpose** Treatment **Masking** Single masking **Masked roles** Outcome assessors Sources for study design Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Outcomes ### Primary outcomes 1. Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24 Timeframe: Day 1 through Week 24 ### Secondary outcomes 1. Proportion of subjects achieving HCV RNA < LLOQ 12 weeks after the last dose of study drugs Timeframe: Day 1 through 12 weeks after the end of treatment 2. Proportion of subjects experiencing virologic failure as measured by HCV RNA RT-qPCR Timeframe: Day 1 through Week 24 Sources for outcomes Source: [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) ## Eligibility **Sex** All **Age groups** Adults, Older adults **Minimum age** 18 Years **Maximum age** 85 Years **Healthy volunteers** No Key Inclusion Criteria: - Use of adequate contraception for females of childbearing potential - Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) - Documented medical history compatible with chronic HCV - Either no liver cirrhosis or with compensated liver cirrhosis - If HIV-1-positive, must meet the following 2 criteria: 1. Antiretroviral (ARV) regimen for >8 weeks prior to screening visit, with CD4 T-cell count >200 cells/mm3 and plasma HIV-1 RNA